About this trial
This study aims to assess the safety tolerability, adherence and effectiveness of genistein as an anti-obesity treatment for children and adolescents. The primary goal is determining how well genistein is tolerated and adhered to by pediatric patients with obesity. Secondary goals include evaluating its impact on body mass index z-scores and cardiometabolic risk factors, such as inflammation.
Participants aged 4-18 will be recruited from the Paediatric HEAL (Healthy Eating, Activity \& Lifestyle) Program at the Children's Hospital - London Health Science Center in London, Ontario. They will receive genistein treatment over 6 months, with interim assessments at 3 and 6 months to monitor efficacy, safetytolerability, and adherence, and efficacy, and potentially increase the dose at the 3-month visit. A final assessment will occur after a 3-month washout to observe any lasting effects.
Blood and urine samples will be collected to analyze various adherence and health markers, including inflammatory and cardiometabolic factors. For participants who are of childbearing potential and have had their first menses, the blood analysis will also include pregnancy testing. Laboratory testing will be performed at baseline, at three and six months while taking genistein and three months after the washout period. Urine samples will also confirm that genistein has been taken appropriately throughout the study.
The study expects that genistein will be well-tolerated by children, reduce BMI z-scores by 0.2 (0.5), and improve cardiometabolic risk factors such as blood pressure, lipid profiles, and inflammation. A sample size of 60 participants has been calculated to achieve statistically significant results, which will inform more extensive studies on genistein's potential for managing pediatric obesity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Children and adolescents aged 4-17 years.
Obesity defined as a BMI z-score ≥ 2 for age and sex, based on World Health Organization (WHO) reference standards.
Stable or increasing BMI after at least 3 months of enrollment in the HEAL program.
Inclusion of participants from all backgrounds, consistent with principles of equity, diversity, and inclusion.
Disqualifiers
Known allergy to Sophora japonica (source of genistein).
Diagnosis of type 2 diabetes (these patients are followed in a separate Diabetes Clinic).
GLP-1 receptor agonists (e.g., Saxenda, Wegovy)
ADHD medications (e.g., Concerta, Vyvanse, Abilify)
Trial design
Single group
Treatments tested in this trial
genistein
DrugParticipants will receive genistein treatment (10-15 mg/kg/day with a maximum dose of 1500mg/day) for 3 months. From the 3-month- to 6-month follow-up, participants will receive a dose of 20-25 mg/kg/day (with a maximum dose of 1500mg/day). According to participant preference, Genistein will be provided as a capsule (250mg per capsule). For participants that are unable to swallow the capsule the capsule may be opened and the powder from the capsule can be mixed with a beverage or food. Interim clinical evaluations will occur at 3 and 6 months to assess, tolerability, adherence and efficacy.. Post-treatment assessment after a 3-month washout will occur at 9 months to determine delayed adverse effects and persistence of beneficial effects after genistein discontinuation.
Treatment groups
Trial outcomes
Primary outcomes
Change in Body Mass Index (BMI) z-score
To assess the impact of genistein on Body Mass Index (BMI) z-scores, calculated using the World Health Organization (WHO) growth reference standards for age and sex. Scale: WHO BMI-for-age z-score Score Range: Typically from approximately -3 to +5 Interpretation: Higher scores indicate greater degrees of obesity, and lower scores indicate improvement in weight status relative to age and sex norms.
Secondary outcomes
Tolerability of Genistein Treatment
To assess the tolerability of genistein as an anti-obesity treatment in children aged 4-18 years with obesity, as measured by the incidence of adverse events, treatment discontinuation rates, and tolerability questionnaires completed by caregivers and participants (e.g., Likert scale or standardized adverse event checklist).
Adherence to Genistein Treatment
To assess adherence to genistein as an anti-obesity treatment in children aged 4-18 years with obesity, as measured by the percentage of prescribed doses taken, recorded through pill counts, caregiver-reported adherence logs, and/or electronic medication monitoring (e.g., MEMS caps).
Other outcomes
Change in Fasting Glucose Levels
To assess the effect of genistein on fasting glucose levels, measured in mmol/L via standard clinical laboratory testing.
Change in Fasting Insulin Levels
To assess the effect of genistein on fasting insulin levels, measured in pmol/L via standard clinical laboratory testing.
Change in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
To assess insulin resistance using HOMA-IR, calculated from fasting insulin and glucose levels. Higher scores indicate greater insulin resistance. Unit of Measure: HOMA-IR index (unitless)
Change in Lipid Profile - Total Cholesterol
To assess changes in total cholesterol levels, measured in mmol/L via clinical laboratory tests.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Western University
Lead sponsor
Western University, Canada
Collaborator
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborator
This trial is not recruiting at the moment. You can still explore other options: